AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02138318 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: chromoendoscopy
Study NCT02233049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT02233049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT02233049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Study NCT00529841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone sodium acetate
Description: Subcutaneous administration of medication via insulin pump
Study NCT03377348 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
Description: intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
Study NCT04904523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test:Blood test
Description: Drop of blood for RNA and metabolic analysis
Study NCT02501889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walnut-rich weight loss diet
Description: Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Walnuts will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
Study NCT02501889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard weight loss diet
Description: Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
Study NCT01416012 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy (standard)
Description: This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
Study NCT01416012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance and Gait training in Individualized sessions
Description: The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement.
Study NCT01416012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kinect
Description: The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
Study NCT01416012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Xbox Kinect
Description: The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
Study NCT02674022 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prenatal supplement
Description: Treatment with a standard and optimized prenatal supplement, dependent on laboratory evaluations of participants.
Study NCT02136875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double dose of Salmeterol + Fluticasone Propionate
Study NCT02136875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management education on the use of a self-administered prescription for exacerbation.
Description: Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription.
Study NCT02136875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Self-administered prescription
Description: An Acute Exacerbation of COPD (AECOPD) is defined as a sustained worsening of dyspnea, cough or sputum production leading to an increase in the use of maintenance medication and/or supplementation with additional medication. In addition, exacerbations should be defined as either purulent or non-purulent.~Standing prescriptions for exacerbation:~1) Purulent exacerbation - Antibiotic: Avelox 400 mg daily for 5 days. 2a) Mild to moderate exacerbation - Combination therapy (SFP - Advair) to be increased as follows: If regular treatment is Advair 250/50 BID then dose should be increased to Advair 500/100 BID for 10 days; if regular treatment is Advair 500/50 BID then increase to Advair 1000/100 BID for 10 days.~2b) Severe exacerbation - Prednisone (oral): 40 mg once daily for 7-10 days
Study NCT01037478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resminostat (4SC-201)
Description: oral administration
Study NCT00648531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balsalazide Disodium Capsules 750 mg
Description: 3x750mg, single dose fasting
Study NCT00648531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colazal® Capsules 750 mg
Description: 3x750mg, single dose fasting
Study NCT03320239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV risk assessment and tailored suggestions
Description: The intervention contains: HIV risk investigation, tailored suggestions and free HIV testing link
Study NCT03320239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV risk behavior assessment
Description: It only contains HIV risk behavior assessment and routine education
Study NCT03320239 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: It only contains HIV/AIDS knowledge assessment and routine education
Study NCT00595582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: curcumin + bioperine
Description: Subjects who are currently in the primary Mild Cognitive Impairment study will be asked to be treated with 5.4 grams of curcumin + bioperine per day (900 mg pills, two pills 3x/day with meals) for 24 months concordant with the last two years of the primary longitudinal Mild Cognitive Impairment study.
Study NCT02669290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided
Description: LV lead placement will be guided by left ventricular systolic function information from MUGA
Study NCT02669290 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-guided
Description: LV lead placement will be conventional posterolateral placement
Study NCT04691466 — intervention group
Intervention type: PROCEDURE
Intervention: Joint replacement
Description: Routinely performed hip- or knee replacement
Study NCT01236404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)
Study NCT01236404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)
Study NCT01236404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)
Description: Once weekly injections for up to four weeks
Study NCT01236404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)
Description: Once weekly injections for up to four weeks
Study NCT01296958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)
Study NCT01296958 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community education campaign
Description: Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.
Study NCT01312766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menotropins
Description: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
Study NCT01312766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menotropins
Description: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
Study NCT00624117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive exercise
Description: home-based exercise program, 2 to 3 exercise sessions per week
Study NCT03390907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid APC
Description: Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.
Study NCT00792142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
Study NCT00792142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
Study NCT00691210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Dose escalation scheme (400 mg)~Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells.
Study NCT00632476 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once a day
Study NCT00691210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacinamide
Description: Dose escalation scheme (20, 40, 60, 80, 100 mg/kg rounded to 100 mg)~Niacinamide is a water soluble B-vitamin that has been evaluated for use in the treatment of pellagra, bullous pemphigoid, and as a radiation sensitizer in head and neck cancer.
Study NCT00632476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: A 500-mg vitamin C capsule once a day
Study NCT00691210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Dose escalation scheme (0, 25, 50, 100 mg/m2)~Etoposide is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase II inhibitor.
Study NCT01306617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: tablets
Study NCT01306617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: tablets
Study NCT01306617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablets
Study NCT01306617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: capsules
Study NCT02114970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Randomized- paper consent
Study NCT02114970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Randomized- Tablet-delivered consent
Study NCT02114970 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Focus Group- paper and tablet consent
Study NCT02125539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigating my Journey program
Description: The online relapse prevention program called Navigating my Journey is designed for adolescents who are receiving outpatient treatment for substance abuse. Since the Navigating my Journey program will be available to adolescents 24/7, it is easy for them to access at their convenience. The program functions as an adjunct to treatment and is designed to complement and enhance the work the adolescent does with the counselor during counseling sessions. The core intervention is expected to last for 12 weeks.
Study NCT02125539 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Client participants in the control group will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
Study NCT01254357 — intervention group
Intervention type: OTHER
Intervention: Questionnaire self report
Description: Burn specific outcome measurement and global health measurement
Study NCT01122199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 + AMG479
Description: Escalating doses of RAD001 + AMG479. Starting cohort will be 5 mg RAD001 once daily, continuous + AMG479 12 mg/kg on Day 1 and 15 of each 28 day cycle.
Study NCT03481959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods).
Study NCT03481959 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods).
Study NCT03675958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Johnstone's Pressure Splint
Description: the intervention consists in the application of two tools used for the treatment of spasticity post - CVD. Johnstone's Pressure Splint added Stretching
Study NCT03675958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching
Description: the intervention consists in the application of one tool used for the treatment of spasticity post - CVD. Just Stretching
Study NCT03675958 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: the intervention consists in the application of one tool used for the treatment of spasticity post - CVD. Just Stretching
Study NCT02782897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulin Therapy
Description: Immunoglobulin is given intravenously 0.4 g/kg per day for five consecutive days.
Study NCT02782897 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard management
Description: Standard management includes: the use of mild sedation, blood pressure control, management of elevated intracranial pressure, glucose management, temperature management, airway maintenance, and management of medical complications.
Study NCT02782897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard management
Description: Standard management includes: the use of mild sedation, blood pressure control, management of elevated intracranial pressure, glucose management, temperature management, airway maintenance, and management of medical complications.
Study NCT02526381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danlou Tablets
Description: Five tablets of Danlou Tablets (1.5g) will be given three times a day in addition to regular western medications for the 8 weeks
Study NCT02526381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongmai Yangxin Pills
Description: Forty pills of Tongmai Yangxin Pills (4g) will be given two times a day in addition to regular western medications for the 8 weeks
Study NCT03062800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100-200mg/d,oral ,qn
Study NCT03062800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: (500mg/m\^2) on day 1 of 21-days cycle,ivgtt
Study NCT03062800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: (75mg/m\^2) on day 1 of 21-days cycle, ivgtt
Study NCT03062800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: (AUC=5) on day 1 of 21-days cycle, ivgtt
Study NCT02618330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: retainer
Description: 24 h wearing whether 0.75-mm-thick or 1.00-mm-thick film retainer
Study NCT03361332 — intervention group
Intervention type: OTHER
Intervention: Behavioral and fMRI
Description: Subjects and patients will perform temporal-judgment-tasks (considered an indirect measure of the sense of agency) in an event-related fMRI setting. In the first task, they will hear a sound either caused by a voluntary key press or by the passive displacement of the same finger by the experimenter. Following each trial, subjects will estimate the delay between the finger movement and the subsequent sound, which will be presented at variable latencies after the key press. There will be also control-trials characterized by the active or passive movement with a subsequent sound presented with a delay that excludes causality inferences.
Study NCT04736316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early CCLAD
Description: Community-based client led antiretroviral therapy delivery groups.
Study NCT02341573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: experienced chinese herbal formulas
Description: At the acute stage of asthma :Shegan mixture ; At the remission stage:Huangqi Bushen mixture; 10-30 mL , 2 times a day, for 3 months.
Study NCT02341573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leukotriene receptor antagonist and bronchial relaxant
Description: At the acute stage of asthma : etinoline,twice a day for 7 days; At the remission stage: Singulair, once daily for 3 months.
Study NCT00513422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate and chondroitin
Description: Glucosamine: Two 750mg capsules once daily for two years;~Chondroitin: Two 400mg capsules once daily for two years.
Study NCT00513422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate
Description: Glucosamine: Two 750mg capsules once daily for two years;~Placebo Chondroitin: Two capsules once daily for two years.
Study NCT00513422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chondroitin sulphate
Description: Chondroitin sulphate: Two 400mg capsules once daily for two years;~Placebo glucosamine: Two capsules once daily for two years.
Study NCT00513422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules for glucosamine and chondroitin
Description: Two placebo glucosamine capsules once daily for two years;~Two placebo chondroitin capsules once daily for two years.
Study NCT00795691 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low-carbohydrate diet
Description: ketogenic low-carbohydrate diet in patients with type 2 diabetes
Study NCT00795691 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low-fat diet
Description: low-fat diet in patients with type 2 diabetes
Study NCT03116165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified prolonged exposure therapy
Description: Participants will receive three sessions of modified prolonged exposure therapy.
Study NCT03116165 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention control
Description: Participants will receive three sessions of supportive counselling and psychoeducation
Study NCT00861497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifeprunox
Description: Flexible dosage: 20, 30, or 40 mg/day
Study NCT02912286 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional needle irrigation
Description: conventional side-vented syringe used to deliver irrigant in root canal treatment
Study NCT02912286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: passive ultrasonic irrigation
Description: ultrasonic tip (IrriSafe) activate the irrigant after mechanical preparation in root canal treatment
Study NCT02912286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sonic irrigation
Description: vibringe system is a sonic device that deliver and agitate the irrigant
Study NCT00014534 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: 6 mg sub Q
Study NCT00014534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 60 mg/sq m IV
Study NCT00014534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: 50 mg/ sq m IV
Study NCT00014534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: 1000 mg/ sq m IV for Gem + cis arm and 2000 mg/sq m IV for gem + dox + peg arm